Acquired Immunodeficiency Syndrome represents the most advanced stage of infection with the human immunodeficiency virus (HIV). HIV is spread throughout contact with infected blood or fluids such as sexual secretions. People with Acquired Immunodeficiency Syndrome have weakened immune systems that make them vulnerable to selected conditions and infections. Signs of Acquired Immunodeficiency Syndrome are unusual infections and cancer. Depending on the severity of the infection, treatment may not be beneficial; however, different antiretroviral medications are used to target the virus.
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Acquired Immunodeficiency Syndrome below!
For more information on how to use Laverne, please read the How to Guide.
We have 3833 products for the study of Acquired Immunodeficiency Syndrome that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Acquired Immunodeficiency Syndrome is also known as Immunodeficiency Syndrome, Acquired, Syndrome, Acquired Immunodeficiency, Acquired Immune Deficiency, Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome (aids).
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.